Full Press Release Details
Evaxion expands preclinical bacterial vaccine pipeline in collaboration
with leading pharmaceutical company
COPENHAGEN, Denmark, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech
A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage biotechnology company specializing in the development
of AI-powered immunotherapies, today announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against
an undisclosed bacterial pathogen. The new vaccine project will be a collaboration between Evaxion and an undisclosed leading pharmaceutical
company, leveraging unique assets and know-how from both organizations.
To develop an effective vaccine, Evaxion has initiated discovery activities
for EVX-B3 using both its EDEN and RAVEN AI platforms to identify protective antigens capable of eliciting both a humoral
(antibody) and cellular response to the pathogen. EVX-B3 aims to address a serious global medical issue, targeting a pathogen associated
with repeated infections, increasing incidence and often serious medical complications, and for which no vaccines are currently available.
The project will be a collaborative and co-funded effort between the two companies.
Evaxion's Chief Scientific Officer, Birgitte R n ,
states: "We are thrilled to announce our upcoming collaboration, aimed at jointly investigating the capabilities of our AI platforms
to design a groundbreaking vaccine targeting this specific pathogen. We strongly believe that this collaboration will further validate
the power of AI to benefit global health through the design of unique vaccines against serious medical conditions."
EDEN is a proprietary AI platform capable
of rapidly identifying those antigens that will trigger a robust and highly protective immune response against virtually any bacterial
infectious disease. EDEN is fully AI-driven and designed to identify vaccine candidates faster and cheaper than current state-of-the-art
methods. With EDEN , we take a novel approach to vaccine development to combat the rising global issue of antibiotic resistance.
For more information, visit our website.
RAVEN is a proprietary AI platform that
rapidly identifies vaccine candidates against existing, emerging, and mutating viral diseases. We are developing next-generation vaccine
candidates that aim to simultaneously trigger potent B- and T-cell responses. Current vaccines against viral infection are challenged
by fading efficacy and evasion by mutating viruses. With RAVEN , the addition of the T-cell component is designed to secure broader,
more durable protection. For more information, visit our website.
Evaxion Biotech A/S is a clinical-stage biotech
company developing world-leading AI platforms. Evaxion's proprietary and scalable technologies harness the power of artificial intelligence
to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. The company
is committed to transforming patients' lives with unmet clinical needs by providing innovative and targeted treatment options. For more
information about Evaxion and its groundbreaking immunotherapies, please visit www.evaxion-biotech.com.
Forward-looking statement
This announcement contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934,
as amended. The words "target," "believe," "expect," "hope," "aim,"
"intend," "may," "might," "anticipate," "contemplate,"
"continue," "estimate," "plan," "potential," "predict,"
"project," "will," "can have," "likely," "should," "would,"
"could," and other words and terms of similar meaning identify forward-looking statements. Actual results may differ
materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to,
risks related to: our financial condition and need for additional capital; our development work; cost and success of our product
development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our
AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third
parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government
regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the
impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on
our business from the worldwide COVID-19 pandemic and the ongoing conflict in the region surrounding Ukraine and Russia; and other
uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to
the risk factors included in our most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange
Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking
statements except as required by law.
Contact information Evaxion Biotech
A/S Christian Kanstrup Chief Executive Officer cka@evaxion-biotech.com
Source: Evaxion Biotech